Company intelligence / Profile preview

Orange Biomed

Ownership: Private
Development stage: Preclinical

Overview

Orange Biomed has developed OBM rapid A1c, a portable at-home device for accurate HbA1c testing. The device uses single-cell analysis to overcome inaccuracies in traditional A1C tests—especially those affecting patients with hemoglobin variants common among African, Asian, and Mediterranean populations. Clinical studies are ongoing globally with Asan Medical Center; the company aims for FDA clearance within a year from April 2023. Early results suggest improved accuracy and accessibility compared to existing methods.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Asan Medical Center (clinical study partner)

Beyond the preview

Go deeper on Orange Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orange Biomed.

Explore the full profile